Caris Life Sciences
PublicCaris Life Sciences is now publicly traded
The data on this page reflects Caris Life Sciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 17, 2025
Last Round
Growth Equity
Apr 7, 2025
Total Funding Raised
$2.12B
Company Overview
Caris Life Sciences is a biotechnology company that provides precision medicine solutions through molecular profiling and artificial intelligence to support cancer treatment decisions.
Sector
Biotech
AI Layer
Application
Keywords
Caris Life Sciences Comparables
Compare Caris Life Sciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tempus | 90% | |
| Guardant Health | 87% | |
| Personalis Inc | 79% |
For institutional investors. Book with your work email.
Caris Life Sciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 17, 2025 | ||||
| Growth Equity | Apr 7, 2025 | ||||
| Debt | Jan 19, 2023 | ||||
| Growth Equity | May 11, 2021 | ||||
| Debt | Oct 27, 2020 | ||||
Debt | Oct 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Caris Life Sciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CPP Investments | Growth Equity |
| Evercore ISI | ipo |
| Perceptive Advisors | Growth Equity |
| Guggenheim Securities | ipo |
| Millennium Management | Growth Equity, Debt |
| Braidwell | Debt, Growth Equity |
| Columbia Threadneedle Investments | Growth Equity |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_revenue_increased_byNov 5, 2026
Caris Life Sciences increases third-quarter revenue 27% year over year to $275.4 million for the quarter ended Sep 30th '26 and raises its 2026 revenue outlook to approximately $1.04 billion-$1.05 billion.
- launchesNov 5, 2026
Caris Life Sciences launches Caris Assure Therapy Response Monitoring, a blood test that helps oncologists assess whether a patient’s cancer responds to treatment.
- has_revenueNov 5, 2026
Caris Life Sciences raises its full-year 2026 revenue forecast from $1.03B to approximately $1.04 billion-$1.05 billion on Nov 4th '26.
- has_valuationOct 20, 2026
Caris Life Sciences, Inc. reaches a $10.3B market cap after going public in Mar '25.
- attends_eventOct 14, 2026
Caris Life Sciences is to present eight studies at ESMO 2026 in Spain in Oct '26, highlighting AI, multi-omics and precision medicine across multiple cancer types.
For institutional investors. Book with your work email.
Caris Life Sciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.